Lifecare Asa · OSL:LIFE
Lifecare Asa — Investor Presentation (September 2021)
25 slides from Lifecare Asa's investor presentation, Sep 21, 2021
Slide 1: Lifecare investor presentation
Lifecare investor presentation September 2021 1
Slide 2: Disclaimer
Disclaimer The information in this presentation has been prepared by Lifecare (the “Company”). This presentation does not constitute a recommendation regarding any securities of the Company. By accepting to attend this presentation and/or receive this information, you agree to be bound by the follow
Slide 3: Content overview
Content overview Why invest in Lifecare Investment highlights Team 3
Slide 4: Why invest in Lifecare?
Why invest in Lifecare? Risk reducing factor Diabetes Lifecares Sencell is a novel and revolutionary continued glucose monitoring device at the size of a grain of rice. Our • Chronic disease - occurs either when the pancreas proprietary osmotic sensing technology will does not produce enough insulin
Slide 5: Diabetes market growing
Diabetes market growing Attractive market outlook Number of adults (20-79) living with diabetes 700 Millions ✓ 10% of global health expenditure is (2045) spent on diabetes - USD 760 billion 578 millions (2030) ✓ 1 in 2 adults with diabetes are undiagnosed - 232 million people 463 Millions (2019) Sou
Slide 6: Glucose measurement market growing
Glucose measurement market growing • The Continuous Glucose Monitoring GLUCOSE SENSOR market 2019 was $3.8 billion, estimated CAGR of 26% 2020-2025 POINT SAMPLE CONTINUOUS SENSOR MINIMALLY NON- FINGER –PRICK URINE INVASIVE • The Blood Glucose Meters market INVASIVE INVASIVE GLUCOMETER DIPSTICK 2020
Slide 7: Content overview
Content overview Why invest in Lifecare Investment highlights Team 7
Slide 8: Investment highlights
Investment highlights THE OPPORTUNITY TO TAKE WELL PROTECTED AND MARKET POTENTIAL AS WELL AS CONTROL OF YOUR BLOOD MATURE TECHNOLOGY SYNERGY/PARTNERING SUGAR POTENTIAL 78
Slide 9: Take control – take care
Take control – take care Inject and Long term use and no body worn forget devices Convenient and Lower cost of care simple in use Actionable data Maintain Higher sensitivity control Improved quality of life 9
Slide 10: Sencell - a contributor to solve the diabetes pandemic
Sencell - a contributor to solve the diabetes pandemic Accurate Osmotic pressure correlates 100% with glucose levels No calibration needed, User friendly inject and forget Miniature sensor injected Invisible under the skin Real time measurement of Continous measurement glucose levels through osmotic
Slide 11: Technology - accurate and user friendly
Technology - accurate and user friendly 11
Slide 12: Technology – invisible
Technology – invisible Enabled by precise nanoscale 3D-printing Miniaturization Resolution 10nm Print on any substrate material Rapid prototyping within minutes 12
Slide 13: Technology – accurate and continuous
Technology – accurate and continuous Overview in electron microscope: Osmotic pressure sensors - sensor element printed to electrode by a controlled 3d nanoprinting process Membrane area 500 µm 200 µm 20 µm 7 µm Electrode for <1 µm gap between Electrode position at 3D printed 4x1 µm² nanosensor acce
Slide 14: Technology – Sencell model
Technology – Sencell model Sensing element detecting movement 0,2 µm Small body device containing pressure membrane, active chamber, pressure sensor, microelectronics and wireless communication 14
Slide 15: Core technology well protected by patents
Core technology well protected by patents • Composition of membranes Double membrane patent • A pressure sensor with a chamber on each side, where the two chambers have individual semi- 2004-2024 permeable membranes • Valid 2024 Augmented osmotic pressure patent • Apparatus for measuring augmented o
Slide 16: Major milestones
Major milestones ✓ In-vitro testing of basic technology: osmotic pressure, chemistry ✓ Pre-clinical tests with basic technology: single chamber measurement ✓ Pre-Clinical tests with improved technology: dual chamber measurement ✓ Miniaturization of sensing element – shrinking the product to a grain
Slide 17: Value-driven future milestones
Value-driven future milestones Initiating product development Lifecare Sencell Prototype Conduct human Conduct human Market launch fabrication for clinical trials – pilot CE mark clinical trials through partnering clinical trials study 1H 2022 1H 2022 2H 2022 1H 2023 Q4 2023 Lifecare Nanobiosensors
Slide 18: Lifecare potential
Lifecare potential Leveraging Lifecare’s validated technology Technical development platform for maximum value generation Lab acquired by Lifecare Sept. 2021 Aim to accelerate and expand the pipeline Chemistry research Seek strategic partnerships to complement our Artificial pancreas strengths 18
Slide 19: Product development agreement Sanofi
Product development agreement Sanofi Sanofi-Avenis Group sponsor the development program for miniaturizing the Sencell Glucose sensor with funding of EUR 290.000 based on completion of defined development phases The Development Agreement is based on a robust evaluation and due diligence process from
Slide 20: FORGETDIABETES - A radically new approach to diabetes treatment
FORGETDIABETES - A radically new approach to diabetes treatment Uniquely capable to Create a bionic exploit physiological glucose sensing and pancreas hormones delivery route Lifecare is the selected enabling Optimising intraperitoneal partner and the only insulin delivery glycaemic control commerci
Slide 21: FORGETDIABETES - A radically new approach to diabetes treatment
FORGETDIABETES - A radically new approach to diabetes treatment www.forgetdiabetes.eu 21
Slide 22: Multiple potential products
Multiple potential products Pipeline has potentially multiple therapeutic areas Chemistry giving the opportunity to expand product areas in combination with Sencell Several patents in preparation 22
Slide 23: Content overview
Content overview Why invest in Lifecare Investment highlights Team 23
Slide 24: Lifecare highly skilled and experienced team
Lifecare highly skilled and experienced team World class expertise in diabetes medicine and technology Prof. David Klonoff Prof. Lutz Heinemann Joacim Holter Prof. Andreas Pfützner Scientific Advisory Board Bo Petersson Board of Directors CEO CSO Chairman Board of Directors Scientific Advisory Board
Slide 25: C Lifecare
C Lifecare